Targeting the Adaptive Stress Response
Through our expertise in stress biology, we have pioneered two differentiated, clinical-stage adaptive stress response modulator programs. Our molecules modulate key aspects of the adaptive stress response that enable tumor survival and limit the ability of T cells to eliminate cancer cells. Our PERK and GCN2 programs have reproducibly resulted in tumor regressions and anti-cancer immunity in numerous tumor models as monotherapy as well as in combination with standard of care therapies.